Rho Kinase Inhibitors - Role in Glaucoma and Cornea Practice

Published

2023-07-25

DOI:

https://doi.org/10.56692/upjo.2023110203

Keywords:

cornea, glaucoma, Rho kinase, ROCK inhibitors

Dimensions Badge

Authors

  • Neha Kumari Cornea, Cataract & Refractive Surgery Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
  • Murugesan Vanathi Cornea, Cataract & Refractive Surgery Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

Abstract

The rho-kinase pathway has been implicated in the pathogenesis of various ocular disorders like glaucoma, Fuchs corneal
dystrophy, diabetic retinopathy, diabetic macular edema, age-related macular degeneration (AMD), ROP. ROCK molecules and
the ROCK pathway regulate multiple physiological functions, such as cell contraction, migration, proliferation, angiogenesis,
chemotaxis, neural protection and vasodilatation, mainly via reorganization of the cytoskeleton. Corneal endothelium increases
endothelial cell proliferation and adhesion and decreases endothelium to mesenchyme transformation. Various studies have
demonstrated their safety and efficacy for ophthalmic use. This review highlights the use of ROCK inhibitors in glaucoma and
corneal diseases.

How to Cite

1.
Kumari N, Vanathi M. Rho Kinase Inhibitors - Role in Glaucoma and Cornea Practice. UPJO [Internet]. 2023 Jul. 25 [cited 2024 May 21];11(02):44-7. Available from: https://upjo.org/index.php/upjo/article/view/197

Downloads

Download data is not yet available.